1108 related articles for article (PubMed ID: 28331080)
1. Evaluation of the Immune Responses to and Cross-Protective Efficacy of Eurasian H7 Avian Influenza Viruses.
Kwon HI; Kim YI; Park SJ; Song MS; Kim EH; Kim SM; Si YJ; Lee IW; Song BM; Lee YJ; Yun SJ; Kim WJ; Choi YK
J Virol; 2017 Jun; 91(11):. PubMed ID: 28331080
[TBL] [Abstract][Full Text] [Related]
2. Inactivated H7 Influenza Virus Vaccines Protect Mice despite Inducing Only Low Levels of Neutralizing Antibodies.
Kamal RP; Blanchfield K; Belser JA; Music N; Tzeng WP; Holiday C; Burroughs A; Sun X; Maines TR; Levine MZ; York IA
J Virol; 2017 Oct; 91(20):. PubMed ID: 28768855
[TBL] [Abstract][Full Text] [Related]
3. A recombinant H7N9 influenza vaccine with the H7 hemagglutinin transmembrane domain replaced by the H3 domain induces increased cross-reactive antibodies and improved interclade protection in mice.
Wang Y; Wu J; Xue C; Wu Z; Lin Y; Wei Y; Wei X; Qin J; Zhang Y; Wen Z; Chen L; Liu GD; Cao Y
Antiviral Res; 2017 Jul; 143():97-105. PubMed ID: 28408133
[TBL] [Abstract][Full Text] [Related]
4. Divergent H7 immunogens offer protection from H7N9 virus challenge.
Krammer F; Albrecht RA; Tan GS; Margine I; Hai R; Schmolke M; Runstadler J; Andrews SF; Wilson PC; Cox RJ; Treanor JJ; García-Sastre A; Palese P
J Virol; 2014 Apr; 88(8):3976-85. PubMed ID: 24453375
[TBL] [Abstract][Full Text] [Related]
5. Development of influenza H7N9 virus like particle (VLP) vaccine: homologous A/Anhui/1/2013 (H7N9) protection and heterologous A/chicken/Jalisco/CPA1/2012 (H7N3) cross-protection in vaccinated mice challenged with H7N9 virus.
Smith GE; Flyer DC; Raghunandan R; Liu Y; Wei Z; Wu Y; Kpamegan E; Courbron D; Fries LF; Glenn GM
Vaccine; 2013 Sep; 31(40):4305-13. PubMed ID: 23891795
[TBL] [Abstract][Full Text] [Related]
6. A Bivalent Heterologous DNA Virus-Like-Particle Prime-Boost Vaccine Elicits Broad Protection against both Group 1 and 2 Influenza A Viruses.
Jiang W; Wang S; Chen H; Ren H; Huang X; Wang G; Chen Z; Chen L; Chen Z; Zhou P
J Virol; 2017 May; 91(9):. PubMed ID: 28179535
[TBL] [Abstract][Full Text] [Related]
7. L226Q Mutation on Influenza H7N9 Virus Hemagglutinin Increases Receptor-Binding Avidity and Leads to Biased Antigenicity Evaluation.
Wang Y; Lv Y; Niu X; Dong J; Feng P; Li Q; Xu W; Li J; Li C; Li J; Luo J; Li Z; Liu Y; Tan YJ; Pan W; Chen L
J Virol; 2020 Sep; 94(20):. PubMed ID: 32796071
[TBL] [Abstract][Full Text] [Related]
8. Protective efficacy of an inactivated chimeric H7/H5 avian influenza vaccine against highly pathogenic avian influenza H7N9 and clade 2.3.4.4 H5 viruses.
Peng C; Hou G; Li J; Wang S; Wang Y; Cheng S; Yu X; Jin J; Jiang W
Vet Microbiol; 2018 Sep; 223():21-26. PubMed ID: 30173747
[TBL] [Abstract][Full Text] [Related]
9. Immunogenicity and Protection Against Influenza H7N3 in Mice by Modified Vaccinia Virus Ankara Vectors Expressing Influenza Virus Hemagglutinin or Neuraminidase.
Meseda CA; Atukorale V; Soto J; Eichelberger MC; Gao J; Wang W; Weiss CD; Weir JP
Sci Rep; 2018 Mar; 8(1):5364. PubMed ID: 29599502
[TBL] [Abstract][Full Text] [Related]
10. H5 N-terminal β sheet promotes oligomerization of H7-HA1 that induces better antibody affinity maturation and enhanced protection against H7N7 and H7N9 viruses compared to inactivated influenza vaccine.
Khurana S; Coyle EM; Verma S; King LR; Manischewitz J; Crevar CJ; Carter DM; Ross TM; Golding H
Vaccine; 2014 Nov; 32(48):6421-32. PubMed ID: 25284811
[TBL] [Abstract][Full Text] [Related]
11. Recombinant virus-like particles elicit protective immunity against avian influenza A(H7N9) virus infection in ferrets.
Liu YV; Massare MJ; Pearce MB; Sun X; Belser JA; Maines TR; Creager HM; Glenn GM; Pushko P; Smith GE; Tumpey TM
Vaccine; 2015 Apr; 33(18):2152-8. PubMed ID: 25772674
[TBL] [Abstract][Full Text] [Related]
12. A cross-reactive human monoclonal antibody targets the conserved H7 antigenic site A from fifth wave H7N9-infected humans.
Li M; Chen L; Wang Q; Hao M; Zhang X; Liu L; Yu X; Yang C; Xu J; Chen J; Gong R
Antiviral Res; 2019 Oct; 170():104556. PubMed ID: 31299269
[TBL] [Abstract][Full Text] [Related]
13. Characterization of Humoral Responses Induced by an H7N9 Influenza Virus-Like Particle Vaccine in BALB/C Mice.
Zhang L; Lu J; Chen Y; Shi F; Yu H; Huang C; Cui L; Shi Z; Jiao Y; Hu Y
Viruses; 2015 Aug; 7(8):4369-84. PubMed ID: 26248076
[TBL] [Abstract][Full Text] [Related]
14. Recombinant influenza H7 hemagglutinin containing CFLLC minidomain in the transmembrane domain showed enhanced cross-protection in mice.
Wang Y; Zhang Y; Wu J; Lin Y; Wu Z; Wei Y; Wei X; Qin J; Xue C; Liu GD; Cao Y
Virus Res; 2017 Oct; 242():16-23. PubMed ID: 28912070
[TBL] [Abstract][Full Text] [Related]
15. A Replication-Defective Influenza Virus Harboring H5 and H7 Hemagglutinins Provides Protection against H5N1 and H7N9 Infection in Mice.
Tian X; Landreth S; Lu Y; Pandey K; Zhou Y
J Virol; 2021 Jan; 95(3):. PubMed ID: 33177192
[TBL] [Abstract][Full Text] [Related]
16. Complete protection against lethal challenge of novel H7N9 virus with heterologous inactivated H7 vaccine in mice.
Tang LH; Lim JH; Kuah LF; Lau YF
Vaccine; 2014 Sep; 32(42):5375-8. PubMed ID: 25130540
[TBL] [Abstract][Full Text] [Related]
17. Cross-reactive mouse monoclonal antibodies raised against the hemagglutinin of A/Shanghai/1/2013 (H7N9) protect against novel H7 virus isolates in the mouse model.
Stadlbauer D; Amanat F; Strohmeier S; Nachbagauer R; Krammer F
Emerg Microbes Infect; 2018 Jun; 7(1):110. PubMed ID: 29925896
[TBL] [Abstract][Full Text] [Related]
18. Vaccine Efficacy of Inactivated, Chimeric Hemagglutinin H9/H5N2 Avian Influenza Virus and Its Suitability for the Marker Vaccine Strategy.
Kim SM; Kim YI; Park SJ; Kim EH; Kwon HI; Si YJ; Lee IW; Song MS; Choi YK
J Virol; 2017 Mar; 91(6):. PubMed ID: 28077631
[TBL] [Abstract][Full Text] [Related]
19. Plant-derived H7 VLP vaccine elicits protective immune response against H7N9 influenza virus in mice and ferrets.
Pillet S; Racine T; Nfon C; Di Lenardo TZ; Babiuk S; Ward BJ; Kobinger GP; Landry N
Vaccine; 2015 Nov; 33(46):6282-9. PubMed ID: 26432915
[TBL] [Abstract][Full Text] [Related]
20. Neuraminidase-Inhibiting Antibody Titers Correlate with Protection from Heterologous Influenza Virus Strains of the Same Neuraminidase Subtype.
Walz L; Kays SK; Zimmer G; von Messling V
J Virol; 2018 Sep; 92(17):. PubMed ID: 29925654
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
